The BARD1 Life Sciences Ltd (ASX: BD1) share price is climbing today following a favourable outcome for the company’s hTERT test.
The post Why the BARD1 (ASX:BD1) share price is climbing 6% today appeared first on The Motley Fool Australia. –
Let’s take a closer look at what the diagnostics company announced.
What’s pushing the BARD1 share price higher?
Investors have been driving up the BARD1 share price after the company provided a positive announcement before market open.
According to its release, BARD1’s hTERT test has been granted Class II In-Vitro Diagnostic (IVD) medical device registration from South Korea’s Ministry of Food and Drug Safety (MFDS).
The pleasing result will now see the company’s hTERT product distributed across South Korea through Mirax Corporation (Mirax). Previously in late 2018, BARD1 entered an exclusive distribution agreement with Mirax for the hTERT test.
Under the initial terms of the deal, BARD1 received a purchase order from Mirax within two days of receiving IVD registration. The first lot of hTERT products is expected to generate revenue of $80,000 for BARD1.
Addressable market opportunity
The South Korean medical device market is considered to be a massive opportunity for BARD1. In 2018, the country’s medical device market was ranked as the ninth-largest in the world and valued at more than US$6.8 billion.
Urological cancer, including bladder cancer, is seen as an increasingly significant health problem in South Korea. A 2011 published report stated that urological cancer accounted for 8% of all known cancers in the country.
What did management say?
BARD1 CEO Dr Leearne Hinch hailed the company’s progress, saying:
Securing Korean registration and our first order from Mirax is the culmination of the BARD1 team’s dedication and effort to expanding the geographical footprint for hTERT in Asia. We are excited to be entering the Korean market and are looking forward to working with the Mirax team to build a strong franchise for hTERT in this key Asian healthcare market.
Mirax CEO Sang-Ju Bae continued on to add:
Mirax believes there is a significant opportunity for hTERT to become a key product in the bladder cancer diagnostic market in Korea. We are confident that the Mirax / BARD1 partnership can position hTERT as a valuable tool for cytologists, pathologists and urologists in the fight against bladder cancer.
The BARD1 share price changed little over the course of 2020, however, in 2021, it has gained more than 460% year to date.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
- These small cap ASX shares surged more than 100% in February
- BARD1 (ASX:BD1) share price plummets 15% on legal proceedings
- Why the BARD1 Life Sciences (ASX:BD1) share price is rocketing another 54% today
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.